Our Research
Drug Discovery Engine
Active Research Programs
ALS Research Collaborative
ARC Data Commons
Our Labs
Publications
AQ Translational Research Center
About Us
ALS TDI: 25 Years
Our Team
ALS TDI FAQ
Schedule a Lab Tour
Contact Us
Our Financials
Take Action
Donate
Attend an Event
Browse Fundraisers
Get Updates
Join Our Study
What is ALS
ALS Treatments
Newly Diagnosed
ALS FAQ
News & Resources
ALS Trial Navigator
News & Insights
Let Us Help
ALS Town Halls
Shop Our Store
Join Our Study
Find ALS Trials
Let Us Help
Sign In
Our Research
Drug Discovery Engine
Active Research Programs
The ARC Study
ARC Data Commons
Our Labs
Publications
AQ Translational Research Center
About Us
ALS TDI: 25 Years
Our Team
ALS TDI FAQ
Schedule a Lab Tour
Contact Us
Our Financials
Take Action
Donate
Attend an Event
Browse Fundraisers
Get Updates
Join Our Study
What is ALS
ALS Treatments
Newly Diagnosed
ALS FAQ
News & Resources
ALS Trial Navigator
News and Insights
Let Us Help
ALS Town Halls
Shop Our Store
Search
Donate
Search
Donate
Articles by Tag - Lou Gehrig
1
2
3
Tuesday, February 7, 2023
Perspectives on Improving the CDC ALS Registry
How many people in the United States have amyotrophic lateral sclerosis (ALS) at any one time is a difficult – and often fraught – question.
read more
Tuesday, February 7, 2023
ALS TDI's 2022 Mid-Year Highlights
We are proud of the progress that we have made thus far in 2022 and we look forward to continuing to share detailed updates at the 2022 ALS TDI Summit on October 14th.
read more
Tuesday, February 7, 2023
Dr. Ammar Al-Chalabi: Why the Terms “Familial” and “Sporadic” ALS can be Misleading
Many in the ALS research community believe that, in light of what we now know about the disease, these terms are not entirely accurate.
read more
Tuesday, February 7, 2023
Tegoprubart: AT-1501’s New Name
AT-1501, a drug invented at the ALS Therapy Development Institute (ALS TDI) and being developed by Eledon Pharmaceuticals, has a new name: tegoprubart.
read more
Tuesday, February 7, 2023
Phase 2 Trial of ALS TDI-Invented AT-1501 Fully Enrolled
The study is expected to be completed in March, 2022, with topline results coming later in the year.
read more
Tuesday, February 7, 2023
Terri Handler: Celebrating a Decade of Work to End ALS
After over a decade of service, ALS TDI’s beloved Development Director, Terri Handler, will be retiring at the end of 2021. Here we talk about her experience and her lasting contribution to ALS TDI’s mission to end ALS.
read more
Tuesday, February 7, 2023
The High Score Hangout: Gamers Streaming to End ALS
At the ALS Therapy Development Institute (ALS TDI), we love it when video gamers show up to support
read more
Tuesday, February 7, 2023
Tavares Speer: Together We Can Change the Future of ALS
"I know that ALS TDI will continue to work until there are treatments for everyone living with ALS, but they need our help." - Tavares Speer
read more
Tuesday, February 7, 2023
2021 ALS TDI Summit Presents Potential Treatments and Innovative New Technology
This year's Summit program included updates about drug discovery research programs in various stages of development at ALS TDI, as well as an extensive update on Project Euphonia from Google.
read more
Tuesday, February 7, 2023
Gill Garcia: Advocating for Veterans with ALS
Much of what causes the 90% of Amyotrophic Lateral Sclerosis (ALS) cases that are sporadic remains a
read more
1
2
3
Showing 1 to 10 of 23 results
Media Contact
marketing@als.net
617-441-7269
Loading...